Drug Profile
Research programme: CXCR4 antagonists - X4 Pharmaceuticals
Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator X4 Pharmaceuticals
- Class Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunodeficiency disorders
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Immunodeficiency-disorders in USA (PO)
- 01 Mar 2019 Preclinical trials in Immunodeficiency disorders in USA (PO) before March 2019 (X4 Pharmaceuticals pipeline, March 2019)